ArticleFrontiers in neurology2026
Cross-modality network phenotyping: a multivariate MRI biomarker signature predicts spatial pathology and clinical severity in EAE.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Evaluating novel therapies for multiple sclerosis requires robust, non-invasive biomarkers. In the experimental autoimmune encephalomyelitis (EAE) model, standard disease evaluations rely heavily on subjective clinical motor scoring and terminal histology, which frequently suffer from a mathematical dilution effect. To address this, we developed an automated, spatially targeted multiparametric magnetic resonance imaging (MRI) pipeline to extract highly specific Methods: EAE was induced in mice using a myelin oligodendrocyte glycoprotein peptide, followed by treatment with either vehicle or fingolimod. At 28 days post-induction, Results: Vehicle-treated mice exhibited severe elevations in gray matter T2 relaxation times and precipitous drops in white matter fractional anisotropy, structurally mapping to localized edema, demyelination, and dense cellular infiltrates. Fingolimod treatment successfully rescued these structural deficits, alongside clinical motor deficits and T-cell infiltration. Localized metrics, specifically ventral white matter fractional anisotropy and a composite fractional anisotropy to T2 ratio, demonstrated treatment effect sizes that exceeded those of the gross clinical paralysis score and corresponding lumbar histopathology. Multivariate predictive modeling showed that the combined MRI panel predicted up to 87.2% of the variance in regional spinal cord pathology and 80.1% of the variance in clinical paralysis. Furthermore, unsupervised principal component analysis extracted an MRI disease score that strongly correlated with clinical disability, global histopathology, and total central nervous system T-cells. Conclusion: Spatially targeted, multiparametric MRI serves as a highly sensitive, objective surrogate biomarker signature. By overcoming the dilution effect, this non-invasive approach provides an objective, continuous metric that complements traditional tissue assays, enhancing the evaluation of multiple sclerosis therapeutics while advancing the reduction of animal use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.